Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

219.72 -11.46 (-4.96%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

23 24 Next >

ALNY Stock Earnings: Alnylam Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 ↗

May 02, 2024

ALNY stock results show that Alnylam Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity

May 02, 2024

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

How Is The Market Feeling About Alnylam Pharmaceuticals? ↗

April 19, 2024

Via Benzinga

Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results

April 18, 2024

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Earnings Scheduled For February 15, 2024 ↗

February 15, 2024

Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million.

Via Benzinga

Alnylam Pharmaceuticals's Earnings Outlook ↗

February 14, 2024

Via Benzinga

(ALNY) - Analyzing Alnylam Pharmaceuticals's Short Interest ↗

February 06, 2024

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

April 09, 2024

Via Benzinga

Analysts Express Confidence in Alnylam's Hypertension Drug Despite Mixed Trial Data ↗

April 08, 2024

The latest findings from Alnylam Pharmaceuticals' KARDIA-2 Phase 2 study are on zilebesiran's efficacy and safety in treating hypertension. Results show significant reductions in systolic blood...

Via Benzinga

Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension

April 07, 2024

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

$100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today ↗

April 02, 2024

Via Benzinga

Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback ↗

March 28, 2024

The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting.

Via Investor's Business Daily

3 Biotech Stocks to Buy on the Dip: March 2024 ↗

March 27, 2024

Some of the best opportunities can be found in dips in some of the top biotech stocks to buy. In fact, here are three.

Via InvestorPlace

Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session

March 20, 2024

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 15 Years ↗

March 18, 2024

Via Benzinga

Billionaire’s Biotech Bets: 3 Stocks Dominating Bill Gates’ Portfolio ↗

March 13, 2024

One of the primary features of Bill Gates biotech stocks is they are all working towards a cure for HIV and related illnesses.

Via InvestorPlace

Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease

March 13, 2024

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Pharma Stock Roundup: Novo Nordisk's New Obesity Pill Data, Roche, AstraZeneca's Pipeline Updates ↗

March 09, 2024

This week, data from Novo Nordisk’s early-stage study on a new weight loss pill called amycretin showed that it could be more effective than Wegovy. Meanwhile, the FDA approved Johnson & Johnson's lung...

Via Talk Markets

Roche/Alnylam Blood Pressure Drug Aces In Mid-Stage Trial, Analyst Says Zilebesiran As Promising Opportunity In Addressing Global Hypertension Challenges ↗

March 05, 2024

Alnylam's KARDIA-2 Phase 2 study on zilebesiran, an RNAi therapeutic for hypertension. Clinically significant reductions in blood pressure observed, with optimistic outlook on upcoming ACC event.

Via Benzinga

Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives

March 05, 2024

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

10 Health Care Stocks Whale Activity In Today's Session ↗

February 29, 2024

Via Benzinga

Here's How Much $100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth Today ↗

February 28, 2024

Via Benzinga

Alnylam to Webcast Presentations at Upcoming March Investor Conferences

February 27, 2024

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Weight-Loss Drugs Have One Big Problem. These Drugmakers Are Taking It On. ↗

February 23, 2024

Weight-loss drugs from Novo Nordisk and Eli Lilly lead to massive weight loss. But not all of that weight loss is healthy.

Via Investor's Business Daily

Goldman Sachs Downgrades Alnylam Pharmaceuticals: Here's What You Need To Know ↗

February 16, 2024

Via Benzinga

Why Is Alnylam Pharmaceuticals Stock Trading Lower On Thursday? ↗

February 15, 2024

Alnylam Pharmaceuticals' updates on HELIOS-B Phase 3 study and FDA clearance for ALN-APP Phase 1 study. Fiscal year 2024 guidance of $1.4 billion–$1.5 billion in combined net product revenues.

Via Benzinga

Why Alnylam Pharmaceuticals Stock Is Sinking Today ↗

February 15, 2024

Alnylam's change to a key clinical trial design appears to have worried investors more than a small Q4 revenue miss.

Via The Motley Fool

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Period Activity

February 15, 2024

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2023 Financial Results

January 29, 2024

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Here's Why Regeneron Pharmaceuticals Just Hit A Record High — Again ↗

January 12, 2024

There's more to like about Regeneron Pharmaceuticals than just Eylea, says one analyst.

Via Investor's Business Daily

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.